Join Growin Stock Community!

Cytosorbents corporationCTSO.US Overview

US StockHealthcare
(No presentation for CTSO)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

CTSO AI Insights

CTSO Overall Performance

CTSO AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

CTSO Recent Performance

-0.33%

Cytosorbents corporation

0.05%

Avg of Sector

-0.31%

S&P500

CTSO PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

CTSO Key Information

CTSO Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

CTSO Profile

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology. Its flagship product is CytoSorb, an extracorporeal cytokine filter for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention and treatment of perioperative complications of cardiopulmonary bypass surgery, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant. The company also develops VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals; CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, as well as removal of anti-A and anti-B blood group antibodies from fresh whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it is involved in the development of BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; DrugSorb, a device to remove toxic chemicals from the blood; and DrugSorb-ATR, an antithrombotic removal system. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.

Price of CTSO

CTSO FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

CTSO Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.17
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
1.28
PB Ratio
5.08
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
77.02%
Net Margin
-30.81%
Revenue Growth (YoY)
-8.97%
Profit Growth (YoY)
11.80%
3-Year Revenue Growth
5.35%
3-Year Profit Growth
22.60%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.17
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
1.28
PB Ratio
5.08
Price-to-FCF
-
Gross Margin
77.02%
Net Margin
-30.81%
Revenue Growth (YoY)
-8.97%
Profit Growth (YoY)
11.80%
3-Year Revenue Growth
5.35%
3-Year Profit Growth
22.60%

  • When is CTSO's latest earnings report released?

    The most recent financial report for Cytosorbents corporation (CTSO) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating CTSO's short-term business performance and financial health. For the latest updates on CTSO's earnings releases, visit this page regularly.

  • What is the operating profit of CTSO?

    According to the latest financial report, Cytosorbents corporation (CTSO) reported an Operating Profit of -2.86M with an Operating Margin of -30.17% this period, representing a growth of 34.9% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is CTSO's revenue growth?

    In the latest financial report, Cytosorbents corporation (CTSO) announced revenue of 9.49M, with a Year-Over-Year growth rate of 1.01%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much cash does CTSO have?

    At the end of the period, Cytosorbents corporation (CTSO) held Total Cash and Cash Equivalents of 9.06M, accounting for 0.2 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does CTSO go with three margins increasing?

    In the latest report, Cytosorbents corporation (CTSO) did not achieve the “three margins increasing” benchmark, with a gross margin of 70.3%%, operating margin of -30.17%%, and net margin of -33.4%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess CTSO's profit trajectory and future growth potential.

  • Is CTSO's EPS continuing to grow?

    According to the past four quarterly reports, Cytosorbents corporation (CTSO)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -0.05. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of CTSO?

    Cytosorbents corporation (CTSO)'s Free Cash Flow (FCF) for the period is -2.59M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 0.73% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of CTSO?

    The latest valuation data shows Cytosorbents corporation (CTSO) has a Price-To-Earnings (PE) ratio of -3.95 and a Price/Earnings-To-Growth (PEG) ratio of 0.02. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.